- Home
- BLUE vs PLX Comparison
BLUE vs PLX Comparison
Compare BLUE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLUE
- PLX
- Stock Information
- Founded
- BLUE 1992
- PLX 1993
- Country
- BLUE United States
- PLX Israel
- Employees
- BLUE N/A
- PLX N/A
- Industry
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLUE Health Care
- PLX Health Care
- Exchange
- BLUE Nasdaq
- PLX Nasdaq
- Market Cap
- BLUE 78.7M
- PLX 79.4M
- IPO Year
- BLUE 2013
- PLX 1998
- Fundamental
- Price
- BLUE $0.30
- PLX $1.68
- Analyst Decision
- BLUE Hold
- PLX
- Analyst Count
- BLUE 10
- PLX 0
- Target Price
- BLUE $3.03
- PLX N/A
- AVG Volume (30 Days)
- BLUE 5.5M
- PLX 439.0K
- Earning Date
- BLUE 11-14-2024
- PLX 11-14-2024
- Dividend Yield
- BLUE N/A
- PLX N/A
- EPS Growth
- BLUE N/A
- PLX N/A
- EPS
- BLUE N/A
- PLX N/A
- Revenue
- BLUE $53,120,000.00
- PLX $45,667,000.00
- Revenue This Year
- BLUE $199.14
- PLX N/A
- Revenue Next Year
- BLUE $186.62
- PLX $88.94
- P/E Ratio
- BLUE N/A
- PLX N/A
- Revenue Growth
- BLUE 144.50
- PLX N/A
- 52 Week Low
- BLUE $0.29
- PLX $0.82
- 52 Week High
- BLUE $5.53
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- BLUE 23.35
- PLX 74.56
- Support Level
- BLUE $0.34
- PLX $1.14
- Resistance Level
- BLUE $0.53
- PLX $1.75
- Average True Range (ATR)
- BLUE 0.04
- PLX 0.12
- MACD
- BLUE -0.01
- PLX 0.05
- Stochastic Oscillator
- BLUE 4.16
- PLX 87.29
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.